Thyroid Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 or older at the time of signing the consent form.
• People who have been diagnosed through a tissue biopsy with one of the following advanced thyroid cancers that cannot be surgically removed, has spread locally, or has spread to other parts of the body: anaplastic thyroid carcinoma (ATC), poorly differentiated thyroid carcinoma (PDTC), or a type of thyroid cancer that no longer responds to radioactive iodine treatment (including papillary or follicular thyroid cancer).
• People with ATC or PDTC who either do not have certain specific gene changes (BRAF V600E, RET fusion, NTRK fusion, or ALK fusion), or who do have those gene changes but have already tried and not responded to the standard targeted treatment for them.
• People with radioactive iodine-resistant thyroid cancer where the cancer meets at least one of these conditions: the cancer does not absorb radioactive iodine, the cancer grew within 12 months of radioactive iodine treatment, the person received a very high cumulative dose of radioactive iodine, the cancer shows up on a specific type of scan (FDG-PET), or prior targeted drug therapy (multi-target TKI) has already been tried and has not worked.
• People who have at least one area of cancer that can be measured on a scan, based on standard measurement guidelines (RECIST v1.1).
• People who are well enough to carry out basic daily activities, as assessed by a standard medical scale (ECOG score of 0, 1, or 2).
• People with a life expectancy of at least 12 weeks.
• People whose blood cell counts and bone marrow function are within acceptable ranges, as confirmed by blood tests (confirm with trial site for exact values).
• People whose liver is functioning adequately, as shown by blood test results within acceptable ranges (confirm with trial site for exact values).
• People whose kidneys are functioning adequately, with kidney filtration above a certain level as calculated by a standard formula (confirm with trial site for exact values).
• People who do not have an active autoimmune disease that requires ongoing systemic (whole-body) treatment.
• People who do not have another active cancer that currently requires treatment.
• People who are willing and able to sign a written consent form.

Who may not be able to join:

• People who have previously received a treatment specifically targeting a protein called TROP2.
• People who have previously been treated with a type of drug called a topoisomerase I inhibitor antibody-drug conjugate.
• People who have previously received certain immune-activating drugs (such as those targeting ICOS, CD40, CD137, GITR, or OX40) or immune cell therapies.
• People who have had another cancer diagnosis within the past 3 years, unless it was a localised skin cancer or early-stage cervical cancer that was fully treated (confirm with trial site for specific exceptions).
• People who have cancer that has spread to the brain or spinal cord that is not well-controlled or is causing symptoms — though people whose brain metastases have been treated and have been stable for at least 4 weeks, and who have been off steroid medications for at least 2 weeks, may still be considered (confirm with trial site).
• People with serious uncontrolled health conditions, including uncontrolled high blood pressure, severe diabetes, or an active infection.
• People who have a history of a lung condition called interstitial lung disease or non-infectious pneumonitis that required steroid treatment, or who currently have a suspected lung condition of this type.
• People who still have side effects from previous cancer treatments that are greater than a mild level (Grade 1), except for hair loss or other effects considered clinically minor.
• People who have had an active autoimmune disease requiring systemic treatment within the past 2 years (standard hormone replacements such as thyroid medication or low-dose steroids are generally not considered in this category — confirm with trial site).
• People who have been taking steroid medications at a dose higher than 10 mg per day of prednisone (or equivalent) within the 10 days before starting the trial, with exceptions for inhaled, topical, or low-dose replacement steroids (confirm with trial site).
• People with a known HIV infection, AIDS, or an active syphilis infection.
• People who have had an organ transplant or bone marrow/stem cell transplant from a donor.
• People with a known serious allergic reaction to the study drugs or their ingredients.
• People who have recently received chemotherapy, radiation, immunotherapy, biological therapy, targeted drug therapy, or other systemic immune treatments and have not completed the required waiting period before joining (confirm with trial site for specific timeframes).
• People who are pregnant or currently breastfeeding.
• People with serious eye conditions that may affect healing of the surface of the eye, such as severe dry eye syndrome or severe meibomian gland disease.

Important: Always verify eligibility with the trial site directly before applying.